Product Description
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Moderna is proactively preparing for a confirmatory efficacy study for mRNA-1010 as early as the 2022/2023 Northern Hemisphere influenza season, if needed. (Sourced from: https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-3-Study-of-Seasonal-Influenza-Vaccine-Candidate-mRNA-1010/default.aspx)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Bulgaria, Canada, Colombia, Denmark, Estonia, Germany, Netherlands, Panama, Philippines, Poland, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Influenza, Human
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| . | P3 |
Active, not recruiting |
Influenza, Human |
2024-12-23 |
|
| mRNA-1083-P101 | P2 |
Active, not recruiting |
Influenza, Human|COVID-19 |
2024-11-29 |
|
| mRNA-CRID-003 | P2 |
Active, not recruiting |
Influenza, Human |
2024-08-09 |
|
| IGNITE P303 | P3 |
Active, not recruiting |
Influenza, Human |
2024-06-24 |